In a challenging year for biotechnology firms, PureTech Health PLC (PRTC) stock has touched a 52-week low, dipping to $16.81.

PureTech also has discovery and preclinical-stage candidates in oncology, including anti-Galectin-9 and Delta-1 antibodies for solid tumours. Image by Gerd Altmann from Pixabay Image ...

PureTech expects to announce topline results in mid-2021. This follows a phase 1 trial of the drug in March testing its safety, tolerabili ty and pharmacokinetic profile in several doses in ...

PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class ...

PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment ...

PureTech has presented data demonstrating high expression of galectin-9 across various solid tumor types and blood cancers and has found that, in several cancers, galectin-9 levels correlate with ...

Check the time stamp on this data. Updated AI-Generated Signals for Puretech Health Plc (PRTC) available here: PRTC. Type a ...

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

GET MORE AI-GENERATED SIGNALS: January 10, 2025, 20:42 pm ET, BY Rick W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

(RTTNews) - Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LYT-200, a first-in-class ...

J.D., Entrepreneur-in-Residence at PureTech who is leading the Gallop Oncology work. "This milestone builds on the FDA’s recognition of LYT-200’s promise, including Orphan Drug designation for AML and ...